Your browser doesn't support javascript.
loading
A Case of Rebound Phenomenon after Cessation of Cyclosporine for Guselkumab Therapy in Psoriasis / 대한피부과학회지
Korean Journal of Dermatology ; : 679-682, 2022.
Artículo en Inglés | WPRIM | ID: wpr-968045
ABSTRACT
Cyclosporine is one of the main therapeutic agents for psoriasis. It is known that psoriasis relapses 2∼3 months after discontinuation of cyclosporine, and exacerbation due to abrupt discontinuation of cyclosporine is uncommon. We report a case of psoriasis that was aggravated by cyclosporine cessation for guselkumab treatment, but improved with continuous administration of guselkumab. A 55-year-old man with a history of psoriasis presented with erythematous scaly plaques on the whole body. He had been treated with cyclosporine for 18 months and had received a subcutaneous injection of guselkumab 1 month previously. Two weeks after the first injection, the patient experienced exacerbation of the lesions. Considering the aggravation caused by abrupt discontinuation of cyclosporine, guselkumab administration was continued. The aggravated psoriatic lesions improved after additional guselkumab injections. At 16 weeks, the Psoriasis Area and Severity Index score was 0, which remained constant thereafter.
Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Idioma: Inglés Revista: Korean Journal of Dermatology Año: 2022 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Idioma: Inglés Revista: Korean Journal of Dermatology Año: 2022 Tipo del documento: Artículo